Mónica Ñañez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mónica Ñañez has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Ascanio Bencosme
Facultad de Ciencias de la Salud, Universidad Autónoma de Santo Domingo, Santo Domingo, República Dominicana
4 shared publications - Carlos Escalante
Departamento de Ginecología, Facultad de Medicina, Universidad de Costa Rica, San José, Costa Rica
4 shared publications Carlos Salinas
Servicio de Obstetricia y Ginecología, Hospital Ángeles, Puebla, México
4 shared publications- Claudia Rey
Asociación Argentina para el Estudio del Climaterio, Buenos Aires, Argentina
4 shared publications - Doris Rodríguez-Vidal
Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, Buenos Aires, Argentina
4 shared publications - Eliana Ojeda
Departamento Académico de Medicina Humana, Universidad Andina del Cusco, Cusco, Peru
4 shared publications
Latest Publications
- 13 October 2026
- Published by Wolters Kluwer Health in Menopause
Regular physical activity is associated with lower odds of bodily pain in midlife women
Objective: To evaluate the association between regular physical activity and bodily pain domain of the SF-36 in midlife women, considering pharmacological and physical factors. Methods: This cross-sectional study included 3,523 women aged 40 to 60 years. Participants reported whether they had generalized body pain, physical activity, menopause status, menopause hormone therapy (MHT) use, psychotropic medication use, and comorbidities. Multivariable logistic regression was used to identify independent predictors of bodily pain. Results: Women reporting regular physical activity (n=1806; 56.3%) had 34% lower odds of bodily pain (OR 0.66; 95% CI: 0.58-0.76), independent of BMI, menopause status, psychotropic drug use, and comorbidities. MHT use showed an even stronger association (OR 0.50; 95% CI: 0.41-0.61). Conversely, obesity (OR 1.61; 95% CI: 1.36-1.92), postmenopause status (OR 1.45; 95% CI: 1.26-1.68), psychotropic drug use (OR 1.45; 95% CI: 1.24-1.70), and comorbidities (OR 1.52; 95% CI: 1.31-1.77) were associated with increased pain risk. Conclusions: Regular physical activity is independently associated with lower odds of bodily pain in midlife women. Exercise programs, in combination with MHT, may contribute to optimizing pain management in this population and warrant further prospective investigation.
- 13 October 2026
- Published by Wolters Kluwer Health in Menopause
Regular physical activity is associated with lower odds of bodily pain in midlife women
Objective: To evaluate the association between regular physical activity and bodily pain domain of the SF-36 in midlife women, considering pharmacological and physical factors. Methods: This cross-sectional study included 3,523 women aged 40 to 60 years. Participants reported whether they had generalized body pain, physical activity, menopause status, menopause hormone therapy (MHT) use, psychotropic medication use, and comorbidities. Multivariable logistic regression was used to identify independent predictors of bodily pain. Results: Women reporting regular physical activity (n=1806; 56.3%) had 34% lower odds of bodily pain (OR 0.66; 95% CI: 0.58-0.76), independent of BMI, menopause status, psychotropic drug use, and comorbidities. MHT use showed an even stronger association (OR 0.50; 95% CI: 0.41-0.61). Conversely, obesity (OR 1.61; 95% CI: 1.36-1.92), postmenopause status (OR 1.45; 95% CI: 1.26-1.68), psychotropic drug use (OR 1.45; 95% CI: 1.24-1.70), and comorbidities (OR 1.52; 95% CI: 1.31-1.77) were associated with increased pain risk. Conclusions: Regular physical activity is independently associated with lower odds of bodily pain in midlife women. Exercise programs, in combination with MHT, may contribute to optimizing pain management in this population and warrant further prospective investigation.
- 6 October 2026
- Published by Wolters Kluwer Health in Menopause
Awareness and clinical impact of the revised FDA warning on menopausal hormone therapy among Latin American physicians. REDLINC XIV
Objective: To evaluate Latin American physicians’ awareness regarding the recent revised statement of the US Food and Drug Administration (FDA) “black box warning” on menopausal hormone therapy (MHT) and to analyze its self-reported impact on clinical practice. Methods: A multicenter cross-sectional study was conducted in thirteen Latin American countries. Physicians caring for peri- and postmenopausal women completed an anonymous survey assessing awareness of the revised FDA communication, perceived clarity, self-reported impact on clinical practice, and MHT prescribing patterns. Bivariate analyses and multivariable logistic regression were performed. Results: A total of 2,166 physicians participated, mainly obstetrician-gynecologists (75.7%) and endocrinologists (9.0%). Overall, 80.7% were aware of the FDA revised statement. In addition, 90.5% considered that the previous warning had overestimated breast cancer risk, and 78.9% believed that the revised communication provides a more balanced view of risks and benefits. Changes in clinical practice were reported by 59.4% of participants, whereas 18.7% reported increased MHT prescribing. Furthermore, 53.3% modified the way they explain breast cancer risk, and 40.4% reported spending more time on patient education and shared decision-making. Physicians with ≤20 years of professional experience and those from specialties other than obstetrics and gynecology or endocrinology were more likely to report that the FDA revised statement would influence their therapeutic conduct. Conclusions: The revised FDA communication appears to have influenced Latin American physicians’ views and self-reported clinical practice, promoting a more balanced view of MHT and encouraging patient education and shared decision-making. However, the increase in MHT prescribing rates was relatively modest, and overall findings should be interpreted cautiously given the cross-sectional design, self-reported nature of the data, and potential selection bias.
- 6 October 2026
- Published by Wolters Kluwer Health in Menopause
Awareness and clinical impact of the revised FDA warning on menopausal hormone therapy among Latin American physicians. REDLINC XIV
Objective: To evaluate Latin American physicians’ awareness regarding the recent revised statement of the US Food and Drug Administration (FDA) “black box warning” on menopausal hormone therapy (MHT) and to analyze its self-reported impact on clinical practice. Methods: A multicenter cross-sectional study was conducted in thirteen Latin American countries. Physicians caring for peri- and postmenopausal women completed an anonymous survey assessing awareness of the revised FDA communication, perceived clarity, self-reported impact on clinical practice, and MHT prescribing patterns. Bivariate analyses and multivariable logistic regression were performed. Results: A total of 2,166 physicians participated, mainly obstetrician-gynecologists (75.7%) and endocrinologists (9.0%). Overall, 80.7% were aware of the FDA revised statement. In addition, 90.5% considered that the previous warning had overestimated breast cancer risk, and 78.9% believed that the revised communication provides a more balanced view of risks and benefits. Changes in clinical practice were reported by 59.4% of participants, whereas 18.7% reported increased MHT prescribing. Furthermore, 53.3% modified the way they explain breast cancer risk, and 40.4% reported spending more time on patient education and shared decision-making. Physicians with ≤20 years of professional experience and those from specialties other than obstetrics and gynecology or endocrinology were more likely to report that the FDA revised statement would influence their therapeutic conduct. Conclusions: The revised FDA communication appears to have influenced Latin American physicians’ views and self-reported clinical practice, promoting a more balanced view of MHT and encouraging patient education and shared decision-making. However, the increase in MHT prescribing rates was relatively modest, and overall findings should be interpreted cautiously given the cross-sectional design, self-reported nature of the data, and potential selection bias.